Epstein Becker Green (EBG) supported a private equity company’s acquisition of a global manufacturer of cardiovascular devices. EBG assembled and led a global team of health regulatory advisors for the transaction. The team conducted due diligence on various health regulatory matters, including Food and Drug Administration quality and regulatory compliance, sales and marketing practices, health regulatory corporate compliance, health information privacy and security, and state device manufacturing and distribution licensure, and assessed global health regulatory transition issues related to the transaction. EBG also led the health regulatory team in supporting the separation of the acquired business from its previous owner after signing, assisting in the negotiation of transition services between the parties, advising on global operating models spanning 37 countries, and managing state licensure transition.
Results may vary depending on your particular facts and legal circumstances.
People
- Chair—Board of Directors / Member of the Firm
- Member of the Firm
- Member of the Firm
- Strategic Advisor
- Member of the Firm